Clinical Trial: Selective Serotonin Reuptake Inhibitors (SSRIs) in Borderline Personality Disorder

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: SSRIs and Self-harm in Borderline Personality Disorder

Brief Summary: The goal of this study is to examine the effectiveness the selective serotonin reuptake inhibitor (SSRI) escitalopram (also known by the trade name "Lexapro") in reducing desire to self-harm and actual self-harming among young adults with borderline personality disorder who are also currently depressed. Subjects will receive either escitalopram or placebo for eight weeks. During this time subjects will be make weekly visits to see the psychiatrist and record their thoughts and feelings several times each day using an electronic diary.

Detailed Summary:
Sponsor: University of Chicago

Current Primary Outcome: self-harm ideation [ Time Frame: pretreatment to 1-week post treatment ]

Self-harm ideation will be assessed using electronic diaries throught the trial from one week pre-treatment to one week post-treatment


Original Primary Outcome: Same as current

Current Secondary Outcome: Depressive symptoms [ Time Frame: pre-treatment to 1 week post-treatment ]

depressive symptoms will be assessed using weekly interviews and electronic diaries throught the trial from one week pre-treatment to one week post-treatment


Original Secondary Outcome: Same as current

Information By: University of Chicago

Dates:
Date Received: April 12, 2010
Date Started: September 2010
Date Completion:
Last Updated: April 7, 2015
Last Verified: April 2015